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Summary 
Effective T cell immune responses require the molecular interplay between adhesive and signaling 
events mediated by the T cell receptor for antigen (TCR) and other cell surface coreceptor molecules. 
In this report, we have distinguished between the role of regulated adhesion and transmembrane 
signaling in coreceptor function using the T cell glycoprotein CD2. By binding its ligands on 
antigen-presenting cell (APC), CD2 serves both to initiate signal transduction events and to 
promote cellular  adhesion. Furthermore, the avidity of CD2 for one ligand, CD58 (LFA-3), 
is regulated by TCR signaling. We have expressed wild type CD2 and a series of mutated CD2 
molecules in an antigen-specific murine T cell hybridoma. Structure-function studies using these 
stably transfected cell lines identify two structurally and functionally distinct regions of the 116 
amino acid (aa) cytoplasmic domain. One region is required for CD2-mediated signal transduction, 
and a separate COOH-terminal 21 aa portion is required for CD2 activity regulation. Cell lines 
expressing CD2 molecules lacking the cytoplasmic segment required for CD2-initiated IL-2 
production retain the ability to upregulate CD2 avidity. Conversely, cell lines expressing CD2 
mutants lacking the cytoplasmic segment required for avidity regulation retain the ability to 
initiate CD2-specific  signaling. In antigen-specific  T  cell responses,  basal binding of CD2 to 
its ligands enhances antigen responsiveness only minimally, whereas regulated avidity and trans- 
membrane signaling are both required for optimal coreceptor function. Taken together, these 
studies demonstrate the independent contributions of regulated adhesion and intracellular signaling 
in CD2 coreceptor function. 
W 
hile the TCR confers recognition of peptide antigens 
in the context of MHC proteins, several other T cell 
proteins contribute to T function by transducing biochem- 
ical signals or by augmenting cellular adhesion (1). CD2 is 
a T cell glycoprotein that plays a dual role in T cell activa- 
tion. Through interactions with its ligands CD58 (LFA-3), 
CD59, and CD48 (reviewed in reference 2), CD2 initiates 
intracellular signaling cascades and enhances intercellular adhe- 
sion to APC. T cell activation is triggered by certain pairs 
of mAb directed against different CD2 epitopes (3), and the 
interaction of CD58 with CD2 enhances antigen-specific T 
activation (4). CD2 and CDlla/CD18 (LFA-1) provide the 
T  cell with two pathways  for regulating cellular adhesion 
(1, 5). Occupancy of the TCP, has been shown to upregulate 
the avidity of both CD2 (6) and LFA-1 (7) for their respec- 
tive ligands, albeit through distinct signaling pathways (7, 8). 
Although the importance of signaling and adhesion is well 
established,  the relative contributions of these processes to 
T  cell coreceptor function and antigen responsiveness have 
been difficult to assess. Here we have used CD2 as a model 
system to dissect these functions. Expression of human wild 
type and mutant CD2 molecules in an antigen-specific mu- 
rine T cell hybridoma has permitted the identification of dis- 
tinct portions of the CD2 molecule required for CD2-mediated 
signaling and TCR-induced changes in CD2 avidity. Func- 
tional studies using cell lines expressing these CD2 mutants 
revealed that signaling and adhesion independently  contribute 
to CD2 function. 
Materials  and Methods 
Celt Lines, Cell Culture, mAbs, and Other Reagents.  The anti- 
CD2  mAbs  9-1  (9), Tl12 and  Tl13 (3),  and  the  hamster 
anti-mouse CD3 e chain mAb 145-2Cll (10) were the kind gifts 
of S. Y. Yang and B. Dupont (Memorial Sloan-Kettering, New 
York), E. L. Reinherz and S. F. Schlossman  (Dana-Farber Cancer 
Institute, Boston, MA), and J. Bluestone (University of Chicago, 
Chicago, IL), respectively. 
The generation of the murine hybridoma, By155.16, has been 
described (11). Hybridoma cell lines were grown in RPMI 1640 
(Mediatech,  ' Inc., Herndon, VA) supplemented as described (4, 6) 
and with either 10% heat-inactivated  FCS (complete medium) or 
10% iron-supplemented bovine serum (both from Sigma Chem- 
ical Co., St. Louis, MO).  Dandi cells were grown in complete 
medium containing 20% FCS. 
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N327D, and CD2-AT227 have been described (4, 6). The CD2 mu- 
tants 264DE, 262AADE, 260AAAADE, A260-65, and A274-279 
were produced by site-directed mutagenesis using the Muta-Gene 
kit (Bio-Rad, Richmond, CA). The anti-sense oligonucleotides used 
for mutagenesis were: 264DE: 5'AGGTC~CTGGGACTCATCAC- 
CAGGTGGTGG Y; 262AADE: 5'CTGGGACTCATCAGCAGC- 
TGGTGGAGGAGG  Y;  260AAAADE:  5'CTCATCAGCAGC- 
TGCTC~AGGAGGATGTTG  Y;  A260-265:  5'AGGTGCCTG- 
GGAAGGAGGATTTG  3'; A274-279: 5' CTGGTGCTGAAC- 
GGGACGAT  ACT 3';  A228-287:  5' AGCTACTCTGTGAGG- 
CCTTGTCTCCAGCTC 3'; A227-307: 5' TGGCTGAACTCG- 
AGGTGTCTCCAGCTCCTC  3';  A227-323:  5'  TTAATTAGA- 
GGAAC_W.W_~ATGTCTCCAGCTCCTC  Y. A260+ A274 was pro- 
duced by subjecting A260-265 to a second round of mutagenesis. 
Each mutant was subcloned into the pFNeo expression vector (12), 
and the nucleotides  encoding  the cytoplasmic domain  were se- 
quenced. A227-307 and A227-323 were generated using the method 
of Deng and Nickoloff (13). A228-287 was produced by introducing 
a StuI site in the cytoplasmic domain at position  228, digesting 
the resulting construct with StuI creating two DNA species, and 
dosing the larger piece with T4 DNA ligase. 
Transfection, Selection, and Analysis of  lL2 Production  of CD2 Mutant- 
expressing Cell Lines.  Wild type (CD2-XH14) and mutant CD2 
constructs were introduced into By155.16, and G418-resistant cell 
lines were obtained  as described (6,  12). For each CD2 mutant, 
at least four representative cell lines were selected based on CD2 
and TCR surface expression (8), and functional testing was per- 
formed within 8 wk of isolation. Measurement of Ib2 production 
by T cell hybridomas was performed using the IL-2-dependent cell 
line CTLb20 as described (8,  14). 
The expression of mutated CD2 by transfected cell lines was 
confirmed by performing PCR using 1 x  106 cells lysed in 30 ml 
PCR buffer (50 mM KC1, 1.5 mM MgClz, 10 mM Tris, pH 8.35, 
0.45% NP-40, 0.45% Tween-20) in the presence of 100 mg/ml 
proteinase K (Sigma Chemical Co.) for 1 h at 65~  5 ml of this 
reaction, an oligonucleotide primer corresponding to aa positions 
191-198 of the CD2 transmembrane region  (5' GGCATATGTG- 
GAGGAGGCAGCCTC  3'),  and a primer  (5' GGCTGAGTTC- 
GAAGATGCAGAGGT 3') corresponding  to the 3' untranslated 
region of CD2 were amplified by PCR. The resulting DNA frag- 
ment was sequenced using  the femtomole  cycle sequencing kit 
(Promega Corp.,  Madison,  WI). 
Microtiter Plate Binding Assay.  The binding of immunoafl~nity 
purified CD58 (15) to polystyrene plates was confirmed by using 
purified anti-CD58 mAb TS2/9 in an ELISA assay  specific  for mouse 
Ig (Vector Labs., Inc., Burlingame, CA). Binding assays were per- 
formed as described (8, 14) and were repeated between three and 
seven times to confirm reproducibility. 
Results 
Production of CD2 Cytoplasmic Mutant-expressing Cell Lines. 
To identify the regions of the cytoplasmic domain required 
for CD2-mediated signaling and avidity regulation, we con- 
structed a series of CD2 cytoplasmic mutants (Fig. 1). These 
CD2  mutants  were  subdoned  into  the  expression  vector 
pFNeo  and  introduced  by  electroporation  into  the 
HLA-DK-specific murine T call hybridoma, By155.16 (11). 
Previous studies have revealed that transfection of human CD2 
into this hybridoma results in cell lines that produce IL-2 
in response to pairs of anti-CD2  mAbs and that  show en- 
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Figure 1.  Schematic  representation of CD2 cytophsmic domain mu- 
tants. The wild type CD2 molecule (16CD2) is shown at the top. Single 
aa substitutions of CD2 are named for the wild type aa, its position in 
the CD2 sequence, and the substituted aa. Multiple aa substitutions are 
named by the position of the first substitution followed  by the substituted 
aa. Internal deletions are named for the aa joined after deletion of the in- 
tervening aa. 
hanced antigen responsiveness when cocultured with APC 
coexpressing HLA-DR, CD58, and CD59 (4, 6,  16). Cell 
lines expressing essentially equivalent levels of both the TCR 
and each mutated CD2 molecule were chosen for further anal- 
ysis (data not shown). To confirm that each of these cell lines 
expressed the correct mutated form of CD2, the nucleotides 
encoding the cytoplasmic domain of CD2 were amplified by 
PCR and  sequenced (data not  shown). 
Identification of a  Cytoplasmic  Segment Required.for CD2- 
mediated IL-2 Production.  Stimulation of each CD2 mutant- 
expressing cell line via the TCR-CD3 complex with immobi- 
lized anti-CD3  mAb resulted in the production of similar 
amounts of IL-2 (Fig. 2 a). In contrast, stimulation of these 
cell lines with a combination of anti-CD2 mAbs (Tl12 plus 
Tl13) revealed three levels of CD2-mediated responses. Cell 
lines  expressing  the  wild  type  (CD2-XH)  and  COOH- 
terminal cytoplasmic point mutants of CD2 (CD2-S326A, 
CD2-N327A, and CD2-N327D) each produced comparable 
amounts of IL-2, 100--150-fold  over background (Fig.  2 b). 
Similarly,  cell  lines  (264DE,  262AADE,  and  260AAA- 
A.DE) expressing cytoplasmic aa substitution mutants of the 
first  PPPGHK motif, previously suggested to be necessary 
for CD2 signaling (4, 15, 17-19), produced equivalent amounts 
of IL-2 as cell lines expressing wild type CD2 when matched 
for responsiveness to anti-CD3 mAb stimulation (Fig. 2 b). 
In contrast, deletion of either of the first (A260-265) or second 
(A274-279) PPPGHR motif resulted in a 10-30-fold reduc- 
tion in IL-2 production upon anti-CD2 mAb treatment  as 
compared  to  wild  type  CD2.  Deletion  of both  repeats 
(A260+ A274) or larger internal deletions (A228-287, A227- 
307,  and  A227-323)  resulted  in  a complete loss of CD2- 
initiated IL-2 production (Fig. 2 b). A similar pattern of re- 
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Figure  2.  Stimulation of murine T  cell hybridomas by anti-eD3 or 
anti-CD2 mAbs. (a) IL-2 production by routine T cell hybridomas after 
stimulation with plate-bound anti-eD3 mAb (145-2Cll). 145-2Cll was 
plated at a concentration  of 10 ng/ml. (b) Ib2 production  of murine T 
cell hybridomas after stimulation with Tl12 and Tl13 (1:1,000  dilution 
of ascites). Data is reported as mean  •  SE in U/ml of human rib2. In 
(a) incubation of cell lines in the absence of mAb resulted in the produc- 
tion of <0.05 U/m1 of Ib2. The experiments  shown are representative 
of at least two independent determinations. For each mutant-expressing 
cell line at least four independently  derived cell lines were tested, each 
giving similar results. 
sponsiveness  was observed when these CD2 mutants were 
tested for their ability to increase intracellular cAMP levels 
after stimulation with an anti-CD2 mAb (data not shown). 
These observations  demonstrate that CD2 signal transduc- 
tion requires the integrity of at least one of the two PPPGHR 
cytoplasmic motifs located between aa residues 260 and 279. 
The Cytoplasmic Portions Required  for CD2.raediated Signaling 
and TCR-induced Regulation of  CD2 Avidity Are Distinct.  The 
ability of these CD2 mutants to bind immunoailinity purified 
CD58 under resting and activated conditions was then de- 
termined using an in vitro binding assay. CD2-  hybridomas 
did not bind CD58 under any conditions (Fig.  3). In con- 
trast, each CD2-expressing hybridoma bound CD58 equiva- 
lently with basal binding ranging between 6 and 12%. As 
reported previously (6), anti-CD3 mAb or PMA stimulation 
of hybridomas expressing wild type CD2 or a single aa sub- 
stitution of CD2 at position 326 (CD2-S326A) resulted in 
a two- to threefold enhancement of binding to CD58 (Fig. 
3). Single aa substitutions of the COOH-terminal asparagine 
(CD2-N327A or CD2-N327D)  completely abrogated anti- 
CD3- or PMA-induced regulation of CD2 avidity, without 
By155.16  ~. 
CD2-XH219  .......  (([-~ 
CD2-SS26A-It ~  ..............  :"" ( :1~" 
CD2-N32~A-10 L  .............  f(f--- 
CD2-N327D-I 5  ~ ............  ((((((f" t----. 
l//////////~ 
264DEo12 
262AADE-51  ~7z7777-(~  r--, 
]///////~ 
260AAAADE-40 
l  ' 
A260-265-52  .......  (((((((f---" 
A274-279-62  [//...////////~  i 
A260+A274-60 
I 
A228-287-3  t .........  (((((([-..., 
A227-307-6  ((((l-" 
l///////////// 
A227.323-3  (I--7 
AT227-34  ~ ...........  ((:a.,  ' 
I 
0  10  20 
Cells Bound (%) 
30 
Figure  3.  Binding of routine hybridomas to CD58. Cell lines were 
stimulated with no stimulus (~, striped Mrs), 10/tg/ml anti-CD3 mAb 
145-2Cll (black bars), or 50 ng/ml PMA (white bars) for 10 rain and plated 
onto immunoaifinity purified CD58. The percentage of cells specifically 
bound after 30 rain is shown (mean  •  SE for four independent experi- 
ments). Four to six cell lines of each CD2-mutant expressing cellline were 
tested. 
affecting the ability of these cell lines to signal via CD2 (Fig. 
3 and Reference  6). 
To  determine  whether  CD2  avidity  regulation  was  a 
separable function or was dependent upon CD2-initiated IL-2 
production, we analyzed the ability of cell lines expressing 
CD2 signal transduction mutants for their ability to upregu- 
late CD2 avidity. Stimulation ofceU lines expressing the CD2 
mutants lacking both PPPGHK motifs (A260+ A274), lacking 
the aa residues between 228 and 287 (A228-287), or lacking 
the aa between residues 227 and 307 (A227-307) resulted in 
an increase in CD2 adhesiveness comparable to cells expressing 
wild type CD2 (Fig. 3). These cell lines did not produce any 
IL-2 after stimulation with anti-CD2 mAbs (Fig. 2 b), but 
retained the ability to upregulate CD2 avidity  after T  cell 
activation,  demonstrating that CD2-mediated signaling and 
the regulation of CD2 avidity were independent functions. 
Deletion of the cytoplasmic  domain between residues 227 
and 323 (A227-323) or deletion of the COOH-termiml 100 aa 
(CD2-AT227) completely abrogated the ability of cell lines 
not only to respond to anti-CD2 mAbs but also to upregu- 
late CD2 avidity (Figs. 2 b and 3). These observations  dem- 
onstrate that the cytoplasmic regions required for CD2 avidity 
regulation and CD2-mediated signal transduction are distinct 
and define a 21 aa region required for CD2 avidity regulation. 
Avidity Regulation and Transmembrane Signaling Contribute 
Independently to CD2 Coreceptor Function.  The interaction 
of CD2  with  its ligands contributes  significantly to  the 
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Although specific for HLA-DR,  the parental  CD2-  hy- 
bridoma By155.16 responds  poorly to  stimulation by the 
HLA-DR +  , CD58 + human B cell line Daudi in the absence 
of expression of a human coreceptor  such as CD2 (6). To 
determine the contributions of CD2 avidity regulation and 
signaling to antigen responsiveness, cell lines expressing mu- 
tated CD2 molecules were stimulated with Daudi cells, and 
IL-2 production was measured. Expression of the wild type 
CD2 (CD2-XH219) or a single aa substitution of CD2 that 
does not affect either CD2 signaling  or avidity regulation 
(CD2-S326A) resulted in a 40-50-fold enhancement of IL-2 
production over the parental CD2-  hybridoma (Fig. 4), as 
described (6,  16). 
Cell lines expressing CD2 mutants defective  for both avidity 
regulation and CD2 signaling  (e.g., A227-323; Fig. 4) en- 
hanced IL-2 production only slightly, two- to threefold over 
the  CD2-  hybridoma,  confirming that  basal binding of 
CD2 to its ligands contributes to coreceptor function (4, 20). 
Daudi stimulation of cell lines expressing single aa substitu- 
tions of CD2 that were unable to upregulate CD2 avidity 
(CD2-N327A or CD2-N327D) enhanced antigen responsive- 
ness, but not as welt as cell lines expressing wild type CD2 
(Fig. 4). These cell lines retained the ability to initiate CD2- 
dependent signal transduction. Conversely,  cell lines expressing 
CD2 mutants defective in CD2-mediated signaling (A228- 
287 or A227-307) but completely functional in their ability 
to regulate CD2 avidity also exhibited a partial ability to en- 
hance IL-2 production (Fig. 4). Thus, the loss of either CD2 
avidity regulation or signaling function both resulted in par- 
tial defects in CD2 coreceptor function. These observations 
define three components of CD2 function that each contribute 
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Figure 4.  Antigen-specific response  of routine  T  cell hybridomas. 
CD2-  or CD2-expressing murine T  cell hybridomas were cocultured 
with irradiated Daudi cells for 24 h, and the resulting IL-2 quantified. 
Results are shown as the mean +  SE for each point and are representative 
of three independent experiments. Cell lines expressing wild type CD2 
(--0-), CD2-S326A (...0.'), CD2-N327A (-q3--), CD2-N327D (-A-), 
A228-287  ('"A-"), A227-307 (..i!"),  A227-323 (-C]--), and no CD2 
(X) are shown. For each mutant-expressing cell line, two to four indepen- 
dently derived cell lines were tested, each giving similar results. 
to antigen responsiveness: basal ligand binding, regulated 
ligand avidity, and signal transduction. 
Discussion 
This report identifies distinct portions of the CD2 cyto- 
plasmic domain that separately regulate intracellular signaling 
and CD2 avidity for ligand. Basal  binding of CD2 to its ligands 
enhances antigen responsiveness only modestly.  Regulated 
CD2 avidity and CD2 signal transduction both participate 
in the T cell response to antigen. Thus, coreceptor-mediated 
adhesion and transmembrane signaling independently con- 
tribute to T  cell activation. 
The repeated motif PPPGHR is involved in coupling CD2 
to intraceUular signaling pathways. Deletion of either motif 
resulted in a partial defect in CD2 signaling (Fig. 2 b), con- 
sistent with a previous study involving a CD2 deletion mu- 
tant truncated between the two motifs (19). Although the 
substitution of His-Arg at aa 264/265 with Asp-Glu (264DE) 
has been reported to abrogate CD2-mediated signaling (19), 
we have observed that this mutant produces essentially equiva- 
lent amounts of IL-2 after stimulation with pairs of anti- 
CD2 mAbs when compared to wild type CD2 in over 50 
cell lines derived from two independent transfections. In ad- 
dition, the ability of the 262AADE and 260AAAADE mu- 
tants to respond to stimulation by a pair of anti-CD2 mAbs 
confirms the results obtained with the 264DE mutant. Simple 
substitutions  within the first repeat (this report) or in the 
second repeat (19) are thus insufficient to abrogate CD2 sig- 
naling and, by inference, coupling to downstream elements. 
CD2 signaling requires coexpression of the TCR (21). Re- 
cent studies have suggested that the cytoplasmic portion of 
the TCR ~" chain (22) plays an important role in CD2 sig- 
naling.  In addition, CD2 has been shown to coprecipitate 
with a number ofT cell molecules including CD3 e, CD45, 
CD5, TCR ~', p56  lck, and p59~ (reviewed in reference 2). 
Interestingly, the repeated motif identified here as important 
for CD2  signaling  resembles, but  is not identical  to,  the 
proline-rich SH3 binding site (23). 
Mutational analysis of the COOH-terminal portion of the 
CD2 molecule has identified a 21-aa segment required for 
TCR-induced regulation of CD2 avidity. Underscoring its 
evolutionary importance, this cytoplasmic segment retains the 
greatest degree of conservation among the human, rat, and 
mouse CD2 molecules (24). Since CD2 is not a substrate 
of PKC (25), TCR signaling or PMA treatment likely acts 
on intracellular  molecules that, in turn, interact with this 
portion of the cytoplasmic domain to effect changes in CD2 
avidity. 
The mutational analysis of CD2 presented here identifies 
two distinct portions of the cytoplasmic domain required for 
CD2 avidity regulation and CD2 signaling. Since these cy- 
toplasmic segments appear to function separately, these do- 
mains may interact  with different intraceUular proteins.  A 
similar division of function has recently been reported for 
the platelet-derived growth factor receptor, in which separable 
cytoplasmic SH2 regions have been shown to bind either GAP 
or PI-3-kinase,  and to couple this receptor  to distinct sig- 
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as overexpression  of the cytoplasmic segments defined here 
may permit the identification of CD2 binding sites with mol- 
ecules described to coassociate with CD2 as well as with other 
proteins. 
The T  cell hybridoma By155.16  requires  coreceptor ex- 
pression for optimal antigen responsiveness.  Consequently, 
this cell line has facilitated comparison of the contributions 
of CD2 signaling and regulated adhesion to antigen-driven 
T cell activation. The analysis of CD2 mutants defective in 
signaling yet fuUy  capable of regulated adhesion, demonstrates 
that increased CD2 adhesion augments a T cell response to 
antigen in the absence of CD2-mediated signal transduction. 
Conversely,  CD2 signaling contributes to antigen respon- 
siveness in the absence of CD2 avidity regulation. Both of 
these functions are required for optimal CD2 coreceptor func- 
tion. Although these studies have focused on CD2 coreceptor 
function, it will be interesting to compare the molecular mech- 
anisms of CD2 function with those of other T cell coreceptor 
molecules. Further analysis of the role of CD2 in T cell acti- 
vation and adhesion will serve as a useful model system in 
the understanding of the molecular events involved in T cell 
activation. 
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